The role of cyclooxygenases in neurotoxicity of amyloid β peptides in Alzheimer's disease;Znaczenie cyklooksygenaz w neurotoksyczności peptydów amyloidu β w chorobie Alzheimera

Neurologia i Neurochirurgia Polska

Volumn 44, Issue 1, 2010, Pages 65-79

  Ca̧kała, Magdalena ^a   Strosznajder, Joanna B ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Alzheimer's disease; Amyloid ; Cyclooxygenase; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN; OLIGOMER; PROSTAGLANDIN SYNTHASE;

ALZHEIMER DISEASE; GLIA CELL; HUMAN; INFLAMMATION; NEUROTOXICITY; PATHOGENESIS; PROTEIN FUNCTION; REVIEW;

EID: 77951273883     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0028-3843(14)60407-2     Document Type: Review

References (121)

1. Barcikowska M., Bilikiewicz A. Choroba Alzheimera w teorii i praktyce klinicznej. Czelej, Lublin 2004.
2. Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004; 140: 627-638.
3. Strosznajder J.B., Łałowski M.M. Peptydy amyloidu beta w mózgu starczym i w patomechanizmie choroby Alzheimera. W: Strosznajder J.B., Mossakowski J.M. (red.). Mózg a starzenie. Upowszechnianie Nauki - Oświata "UN-O", Warszawa 2001.
4. Hardy J., Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356. (Pubitemid 34790756)
5. Seubert P., Vigo-Pelfrey C., Esch F. i wsp. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992; 359: 325-327.
6. Jarrett J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-4697.
7. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-498.
8. Lambert M.P., Barlow A.K., Chromy B.A. i wsp. Diffusible, nonfibrillar figands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-6453. (Pubitemid 28249033)
9. Hartley D.M., Walsh D.M., Ye C.P. i wsp. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999; 19: 8876-8884.
10. Lesné S., Koh M.T., Kotilinek L. i wsp. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-357.
11. Townsend M., Shankar G.M., Mehta T. i wsp. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572: 477-492.
12. McLean C.A., Cherny R.A., Eraser F.W. i wsp. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-866.
13. Cheng I.H., Scearce-Levie K., Legleiter J. i wsp. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 2007; 282: 23818-23828. (Pubitemid 47328006)
14. Walsh D.M., Klyubin I., Fadeeva J.V. i wsp. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539. (Pubitemid 34288854)
15. Shankar G.M., Bloodgood B.L., Townsend M. i wsp. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866-2875.
16. Johnson LV, Leitner WE, Rivest A.J. i wsp. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002; 99: 11830-11835.
17. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
18. Tuppo E.E., Arias H.R. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37: 289-305.
19. Lue L.F., Brachova L., Civin WH. i wsp. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 1996; 55: 1083-1088. (Pubitemid 26338020)
20. Combs C.K., Karlo J.C., Kao S-C. i wsp. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001; 21: 1179-1188.
21. Walker D.G., Lue L.F., Beach T.G. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging 2001; 22: 957-966. (Pubitemid 34066564)
22. Ralay Ranaivo H., Craft J.M., Hu W. i wsp. Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 2006; 26: 662-670.
23. Yoshiyama Y., Higuchi M., Zhang B. i wsp. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 53: 337-351. (Pubitemid 46161268)
24. in t'Veld B., Ruitenberg A., Hofman A. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521.
25. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327: 128. (Pubitemid 36876203)
26. Szekely C.A., Thorne J.E., Zandi P.P. i wsp. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23: 159-169. (Pubitemid 38980441)
27. Breyer R.M., Bagdassarian C.K., Myers S.A. i wsp. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-690.
28. Harris S.G., Padilla J., Koumas L. i wsp. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23: 144-150.
29. Bazan N.G. Synaptic lipid signaling: significance of polyunsaturated fatty acids and plateled-activating factor. J Lipid Res 2003; 44: 2221-2233.
30. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157-33160.
31. O'Neill G.P., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-160. (Pubitemid 23265121)
32. Kołaczkowska E. Cyklooksygenazy. I. Rola w odczynie zapalnym. Post Biol Kom 2002; 29: 533-554.
33. Hinz B., Brune K. Cyclooxygenase-2 - 10 years later. J Pharmacol Exp Ther 2002; 300: 367-375.
34. Consilvio C., Vincent A.M., Feldman E.L. Neuroinflammation, COX-2, and ALS - a dual role? Exp Neurol 2004; 187: 1-10.
35. Kis B., Snipes J.A., Busija D.W. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005; 315: 1-7.
36. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-910. (Pubitemid 39202493)
37. Yermakova A.V., Rollins J., Callahan L.M. i wsp. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999; 58: 1135-1146. (Pubitemid 29519837)
38. Horton E.W., Main I.H. Identification of prostaglandins in central nervous tissues of the cat and chicken. Br J Pharmacol Chemother 1967; 30: 582-602.
39. Ramwell P.W., Shaw J.E. Spontaneous and evoked release of prostaglandins from cerebral cortex of anesthetized cats. Am J Physiol 1966; 211: 125-134.
40. Shaw K.N., Commins S., O'Mara S.M. Deficits in spatial learning and synaptic plasticity induced by the rapid and competitive broad-spectrum cyclooxygenase inhibitor Ibuprofen are reversed by increasing endogenous brain-derived neurotrophic factor. Eur J Neurosci 2003; 17: 2438-2446. (Pubitemid 36793752)
41. Yamagata K., Andreasson K.I., Kaufmann W.E. i wsp. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-386. (Pubitemid 23250354)
42. Piomelli D. Eicosanoids in synaptic transmission. Crit Rev Neurobiol 1994; 8: 65-83.
43. Chen C, Magee J.C., Bazan N.G. Cyclooxygenase-2 regulates prostaglandin E-2 signaling in hippocampal long-term synaptic plasticity. J Neurophysiol 2002; 87: 2851-2857. (Pubitemid 34670665)
44. Chen C., Bazan N.G. Endogenous PGE2 regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons. J Neurophysiol 2005; 93: 929-941.
45. Morita I., Schindler M., Regier M.K. i wsp. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995; 270: 10902-10908.
46. Bhattacharya M., Peri K.G., Almazan G. i wsp. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 1998; 95: 15792-15797. (Pubitemid 29018779)
47. Netland E.E., Newton J.L., Majocha L.E. i wsp. Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol Aging 1998; 19: 201-204.
48. Mackenzie I.R., Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998; 50: 986-990.
49. Hoozemans J.J., Rozemuller A.J., Janssen I. i wsp. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol 2001; 101: 2-8.
50. Maślińska D., Woźniak R., Kaliszek A. i wsp. Expression of cyclooxygenase-2 in astrocytes of human brain after global ischemia. Folia Neuropathol 1999; 37: 75-79.
51. Hirst W.D., Young K.A., Newton R. i wsp. Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system. Mol Cell Neurosci 1999; 13: 57-68.
52. O'Banion M.K. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999; 13: 45-82.
53. Hüll M., Müksch B., Akundi R.S. i wsp. Amyloid beta peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes. Neurochem Int 2006; 48: 663-672.
54. Bezzi P., Carmignoto G., Pasti L. i wsp. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391: 281-285.
55. Iadecola C., Niwa K., Nogawa S. i wsp. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 2001; 98: 1294-1299. (Pubitemid 32121226)
56. Iadecola C., Sugimoto K., Niwa K. i wsp. Increased susceptibility to ischemic brain injury in cyclooxygenase-1-deficient mice. J Cereb Blood Flow Metab 2001; 21: 1436-1441. (Pubitemid 33117184)
57. Wright D.H., Abran D., Bhattacharya M. i wsp. Prostanoid receptors: ontogeny and implications in vascular physiology. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1343-R1360.
58. Ito S., Okuda-Ashitaka E., Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001; 41: 299-332. (Pubitemid 33733750)
59. Cao C., Matsumura K., Yamagata K. i wsp. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain. Am J Physiol 1997; 272: R1712-R1725.
60. Andreasson K.I., Savonenko A., Vidensky S. i wsp. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 2001; 21: 8198-8209. (Pubitemid 32952775)
61. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 1996; 47: 425-432. (Pubitemid 26324038)
62. Zandi P.P., Breitner J.C. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 2001; 22: 811-817.
63. Ho L., Pieroni C., Winger D. i wsp. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 1999; 57: 295-303. (Pubitemid 29339785)
64. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87: 319-324. (Pubitemid 28370892)
65. Moolwaney A.S., Igwe A.J. Regulation of cyclooxygenase-2 system by interleukin-1beta through mitogen-activated protein kinase signaling pathways: a comparative study of human neuroglioma and neuroblastoma cells. Brain Res Mol Brain Res 2005; 137: 202-212.
66. Jang J.H., Surh Y.J. Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. Free Rad Biol Med 2005; 38: 1604-1613.
67. Hoozemans J.J., Brückner M.K., Rozemuller A.J. i wsp. Cyclin D1 and cyclin E are co-localized with cyclooxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J Neuropathol Exp Neurol 2002; 61: 678-688.
68. Yermakova A.V., O'Banion M.K. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol Aging 2001; 22: 823-836.
69. Hoozemans J.J., Veerhuis R., Rozemuller J.M. i wsp. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 2006; 24: 157-165. (Pubitemid 43294622)
70. Combrinck M., Williams J., De Berardinis M.A. i wsp. Levels of CSF prostaglandin E2, cognitive decline and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006; 77: 85-88. (Pubitemid 43022699)
71. Bate C., Kempster S., Williams A. Prostaglandin D2 mediates neuronal damage by amyloid-beta or prions which activates microglial cells. Neuropharmacology 2006; 50: 229-237. (Pubitemid 43100008)
72. Shie F.S., Montine K.S., Breyer R.M. i wsp. Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol 2005; 15: 134-138.
73. Kadoyama K., Takahashi Y., Higashida H. i wsp. Cyclooxygenase-2 stimulates production of amyloid beta-peptide in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun 2001; 281: 483-490. (Pubitemid 32928181)
74. Qin W., Ho L., Pompl P.N. i wsp. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J Biol Chem 2003; 278: 50970-50977. (Pubitemid 38020330)
75. Xiang Z., Ho L., Yemul S. i wsp. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr 2002; 10: 271-278. (Pubitemid 35315389)
76. Melnikova T., Savonenko A., Wang Q. i wsp. Cyclooxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006; 141: 1149-1162. (Pubitemid 44128685)
77. Xiang Z., Ho L., Valdellon J. i wsp. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 2002; 23: 327-334. (Pubitemid 34312015)
78. Ferrera P., Arias C. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells. Neurochem Int 2005; 47: 589-596. (Pubitemid 41437904)
79. Andersen J.M., Myhre O., Fonnum F. Discussion of the role of the extracellular signal-regulated kinase-phospholipase A2 pathway in production of reactive oxygen species in Alzheimer's disease. Neurochem Res 2003; 28: 319-326. (Pubitemid 36207355)
80. Butterfield D.A., Howard B.J., LaFontaine M.A. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr Med Chem 2001; 8: 815-828.
81. Nagano S., Huang X., Moir R.D. i wsp. Peroxidase Activity of Cyclooxygenase-2 (COX-2) cross-links beta-amyloid (Abeta) and generates Abeta-COX-2 hetero-oligomers that are increased in Alzheimer's disease. J Biol Chem 2004; 279: 14673-14678.
82. Boutaud O., Andreasson K.I., Zagol-Ikapitte I. i wsp. Cyclooxygenase-dependent lipid-modification of brain proteins. Brain Pathol 2005; 15: 139-142.
83. Zagol-Ikapitte I., Masterson T.S., Amarnath V. i wsp. Prostaglandin H (2)-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem 2005; 94: 1140-1145.
84. Liu D.X., Greene L.A. Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res 2001; 305: 217-228.
85. Mirjany M., Ho L., Pasinetti M.G. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J Pharmacol Exp Ther 2002; 301: 494-499.
86. Nagy Z., Esiri M.M., Smith A.D. The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience 1998; 87: 731-739.
87. Hoozemans J.J., Veerhuis R., Rozemuller A.J. i wsp. Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiol Dis 2004; 15: 492-499.
88. Breitner J.C. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 1996; 47: 401-411.
89. Hoozemans J.J., Veerhuis R., Rozemuller A.J. i wsp. Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets 2003; 4: 461-468.
90. in t'Veld B.A., Launer L.J., Breteler M.M. i wsp. Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. Epidemiol Rev 2002; 24: 248-268.
91. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327: 128.
92. McGeer P.L., McGeer E., Rogers J. i wsp. Antiinflammatory drugs and Alzheimer's disease. Lancet 1990; 335: 1037.
93. Pasinetti G.M. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J Alzheimers Dis 2002; 4: 435-445.
94. Andersen K., Launer L.J., Ott A. i wsp. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 1995; 45: 1441-1445.
95. Mackenzie I.R. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation. Neurobiol Aging 2001; 22: 819-822.
96. Weggen S., Eriksen J.L., Das P. i wsp. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-216.
97. Eriksen J.L., Sagi S.A., Smith T.E. i wsp. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta42 in vivo. J Clin Invest 2003; 112: 440-449.
98. Weggen S., Eriksen J.L., Sagi S.A. i wsp. Evidence that non-steroidal anti-inflammatory drugs decrease amyloid beta42 production by direct modulation of gamma-secretase activity. J Biol Chem 2003; 278: 31831-31837.
99. Sastre M., Dewachter I., Landreth G.E. i wsp. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003; 23: 9796-9804.
100. Hirohata M., Ono K., Naiki H. i wsp. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 2005; 49: 1088-1099.
101. Lehmann J.M., Lenhard J.M., Oliver B.B. i wsp. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-3410.
102. Combs C.K., Bates P., Karlo J.C. i wsp. Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferators-activated receptor alpha. Neurochem Int 2001; 39: 449-457.
103. Rich J.B., Rastrusson D.X., Folstein M.F. i wsp. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45: 51-55.
104. Rogers J., Kirby L.C., Hempelman S.R. i wsp. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-1611.
105. Scharf S., Mander A., Ugoni A. i wsp. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197-201.
106. Wilcock G.K., Black S.E., Haworth J. i wsp. Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Abeta42-lowering agent, in Alzheimer's disease (AD): Results of a 12-month phase 2 trial and i-year follow-on study. Alzheimers Dement 2006; 2: S81-S82.
107. Aisen P.S., Schafer K.A., Grundman M. i wsp. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-2826.
108. Soininen H., West C., Robbins J. i wsp. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 23: 8-21.
109. Aisen P.S., Davis K.L., Berg J.D. i wsp. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 2000; 54: 588-593.
110. Firuzi O., Praticò D. Coxibs and Alzheimer's disease: should they stay or should they go. Ann Neurol 2006; 59: 219-228.
111. Ho L., Qin W., Stetka B.S. i wsp. Is there a future for cyclooxygenase inhibitors in Alzheimer's disease? CNS Drugs 2006; 20: 85-98.
112. White W.B., West C.R., Borer J.S. i wsp. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007; 99: 91-98.
113. White W.B., Borer J.S., Gorelick P.B. i wsp. Cardiovascular events in clinical trials involving over 41,000 patients evaluating the cyclooxygenase-2 inhibitor celecoxib. Ann Rheum Dis 2006; 65: 411-417.
114. Chen L.C., Ashcroft D.M. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 2006; 31: 565-576.
115. Salpeter S.R., Gregor P., Ormiston T.M. i wsp. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006; 119: 552-559.
116. Combrinck M.I., Perry V.H., Cunningham C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience 2002; 112: 7-11.
117. Holmes C., El-Okl M., Williams A.L. i wsp. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 788-789.
118. Cakała M., Malik A.R., Strosznajder J.B. Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. Pharmacol Rep 2007; 59: 164-172.
119. Kawano T., Anrather J., Zhou P. i wsp. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006; 12: 225-229.
120. Hoshino T, Nakaya T, Homan T. i wsp. Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. J Biol Chem 2007; 282: 32676-32688.
121. Kotilinek L.A., Westerman M.A., Wang Q. i wsp. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 2008; 131: 651-664.